DRUG · Mapped RxNorm record
Ruxolitinib 20 MG
Normalized identity: ruxolitinib 20 MGView linked drug · Find medicine records ·
Find other trials using this name
Clinical trial
Effect of Ruxolitinib on Tumor Infiltrating Myeloid Cells
NCT03274778
Drugs and interventions used in this trial
1 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
No matching interventions in this trial.
Study at a glance
Registry-backedEffect of Ruxolitinib on Tumor Infiltrating Myeloid Cells
Design: INTERVENTIONAL · Status: WITHDRAWN · Phase: NA
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Prostate Cancerverified · MONDO: prostate cancer
Interventions
Ruxolitinib 20 MGDRUG · verified · RxNorm: ruxolitinib 20 MG
Sponsors & collaborators
Oncology Institute of Southern Switzerlandlead sponsor
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT03274778 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.